Debrisoquin oxidation polymorphism in a Spanish population
- 1 July 1988
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 44 (1), 74-76
- https://doi.org/10.1038/clpt.1988.115
Abstract
The capacity for debrisoquin metabolism was determined in 377 healthy Spanish volunteers by measuring the amount of debrisoquin and its main metabolite, 4-hydroxydebrisoquin, in urine after an oral dose of debrisoquin. Debrisoquin oxidation was polymorphic, with 25 subjects (6.6%) phenotyped as poor metabolizers whereas 352 subjects (93.4%) were classified as extensive metabolizers. The metabolic ratio between debrisoquin and 4-hydroxydebrisoquin (percent of dose) in 6-hour urine samples ranged from 0.03 in extensive metabolizers to 93.5 in poor metabolizers. The proportion of poor metabolizers found is in the range observed in other white populations studied.This publication has 14 references indexed in Scilit:
- ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINEThe Lancet, 1985
- Sparteine Oxidation Polymorphism in DenmarkActa Pharmacologica et Toxicologica, 1985
- Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populationsClinical Pharmacology & Therapeutics, 1985
- A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquinClinical Pharmacology & Therapeutics, 1985
- Inter-ethnic difference in sparteine oxidation among Ghanaians and GermansEuropean Journal of Clinical Pharmacology, 1985
- Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.Proceedings of the National Academy of Sciences, 1984
- Mephenytoin and sparteine pharmacogenetics in Canadian CaucasiansClinical Pharmacology & Therapeutics, 1984
- Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and OrientalsCanadian Journal of Physiology and Pharmacology, 1980
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977